Imagin Medical
Imagin Medical is a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive surgeries. The Company’s initial focus is bladder cancer. The i/Blue Imaging System™ is expected to dramatically improve physicians’ ability to visualize cancerous cells. Working in conjunction with fluorescing imaging agents, this advanced, ultrasensitive imaging technology combines sophisticated opto-electronic functions and near-infrared fluorescence to deliver images far superior to conventional white light systems. Display options include separate blue or white light images, blue and white images displayed side-by-side, or a blending of the blue and white light images into one. Imagin believes the time savings will increase the efficiency of the operating room and potentially reduce healthcare costs by enabling procedures to be performed in the less expensive physician’s office. The i/Blue system was invented by Dr. Stavros Demos at the Lawrence Livermore National Laboratory (LLNL) and validated in collaboration with the UC Davis Comprehensive Cancer Center and Dr. Ralph deVere White, one of the world’s leading authorities on bladder cancer. Imagin now holds the exclusive license to this intellectual property and relocated the final stage of development to the highly-regarded University of Rochester Laboratory for Laser Energetics (LLE) and its affiliated first-class Medical Center. A Research Study using the i/Blue Imaging System prototype was led by Dr. Edward Messing and provided valuable input to the development of the final product for commercialization. Imagin’s engineering team has completed the Proof of Concept Phase and expects the Functional Phase to be completed by end of 2Q2019. As the i/Blue Imaging System becomes established in the urology market, the Company will complete development of the i/Vision Imaging System technology which combines multiple illumination sources into one system. The i/Vision will accommodate the most commonly used fluorescing contrast agents and will potentially enable Imagin to expand into additional surgical specialties.
Imagin Medical is a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive surgeries. The Company’s initial focus is bladder cancer. The i/Blue Imaging System™ is expected to dramatically improve physicians’ ability to visualize cancerous cells. Working in conjunction with fluorescing imaging agents, this advanced, ultrasensitive imaging technology combines sophisticated opto-electronic functions and near-infrared fluorescence to deliver images far superior to conventional white light systems. Display options include separate blue or white light images, blue and white images displayed side-by-side, or a blending of the blue and white light images into one. Imagin believes the time savings will increase the efficiency of the operating room and potentially reduce healthcare costs by enabling procedures to be performed in the less expensive physician’s office. The i/Blue system was invented by Dr. Stavros Demos at the Lawrence Livermore National Laboratory (LLNL) and validated in collaboration with the UC Davis Comprehensive Cancer Center and Dr. Ralph deVere White, one of the world’s leading authorities on bladder cancer. Imagin now holds the exclusive license to this intellectual property and relocated the final stage of development to the highly-regarded University of Rochester Laboratory for Laser Energetics (LLE) and its affiliated first-class Medical Center. A Research Study using the i/Blue Imaging System prototype was led by Dr. Edward Messing and provided valuable input to the development of the final product for commercialization. Imagin’s engineering team has completed the Proof of Concept Phase and expects the Functional Phase to be completed by end of 2Q2019. As the i/Blue Imaging System becomes established in the urology market, the Company will complete development of the i/Vision Imaging System technology which combines multiple illumination sources into one system. The i/Vision will accommodate the most commonly used fluorescing contrast agents and will potentially enable Imagin to expand into additional surgical specialties.
Imagin Medical has raised $7.3M across 1 round. Its most recent round was a Post-IPO Debt of $7.3M in Aug 2022. Full funding history, investors, and team are detailed below.
Funding history
1 round on record.
Unlock the lead investor and full details for this round.
People
Founders, executives, and decision-makers — sourced and refreshed weekly.
See who runs this company — founders and key execs, with titles and LinkedIn profiles, ready to export.
Imagin Medical is featured in
Similar companies
Intellihealth creates medical technology software that aids in diagnosing diseases associated with obesity. One of the company's primary offerings, Evolve, allows healthcare professionals to provide effective obesity treatment to patients, whether through telehealth or in-person consultations.
Ember Copilot is a Software Development firm offering a tool to reduces medical claim denials.
Reimagine Care is a health care company that provides technology-enabled services to support community-based oncology care settings. It aims to make high-quality cancer care more affordable, accessible, and patient-centric. Reimagine Care partners with HC systems and independent physician oncology practices to support value-based oncology care delivery in the community. They do this by providing the people, processes, and a robust technology platform that enables the scalable and effective delivery of high-quality, patient-centric, lower-cost cancer care across multiple care sites, including the home. It was founded in 2020 and is based in Nashville, Tennessee.
QSimulate is currently hiring for various positions such as scientists, software engineers, project managers, and business development, as the team expands. Our office locations include Boston MA, Berkeley CA, and Ghent, Belgium. Remote options are also considered for technical roles. For further details, please contact us at info@qsimulate.com.
100 Healthy Years • Your new routine of 120+ advanced lab tests explained by the world's top doctors
Perelel is a supplement manufacturer designed for various stages of a woman's reproductive life cycle.
House Rx is a health technology platform focused on improving affordability and patient access to specialty medications.
DifferentKind is a software solution designed for dental professionals to focus on patient needs, allowing them to enhance patient results and satisfaction. This ultimately leads to increased trust, loyalty, and revenue for dental practices. The software utilizes AI technology for clinical consultations and executive decision-making.
NextSense opens mind wellbeing with genuine information experiences and useful, logical insight for everyday living. It plans to catalyze cerebrum wellbeing in science and culture. The organization was established in 2020 and is settled in Mountain View, California.
MR3Health is a unique new organization that brings an inventive mix of administration and demonstrated innovation to patients and guarantors to save lives impacted by diabetic neuropathy and lower the expenses of medical services. MR3Health is extraordinarily situated for progress with various assets obscure to most new businesses. These incorporate existing licenses, a FDA cleared clinical gadget upheld by clinical preliminaries, and a supervisory crew with an abundance of business, assembling, and clinical experience. It was sent off in 2015 and is settled in San Antonio, Texas.
MiSalud offers a unique combination of personalized preventative wellness services, along with traditional healthcare via Spanish speaking physicians.
Synchron is a leading implantable brain computer interface company. The stentrode is the first commercial implantable brain computer interface to receive an FDA IDE for in human clinical trials.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.